Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 340Pancreatic function and diabetesDiabetes Management and ResearchDiabetes Treatment and Management

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; none of the 16 sources its claims cite is checked for support yet.

Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man

Open access
Rizza, R. A., Cryer, P. E., Haymond, M. W., Gerich, J. E.·1980·Journal of Clinical Investigation

Abstract

THE PRESENT STUDIES WERE UNDERTAKEN TO ASSESS THE ADRENERGIC MECHANISMS BY WHICH EPINEPHRINE STIMULATES GLUCOSE PRODUCTION AND SUPPRESSES GLUCOSE CLEARANCE IN MAN: epinephrine (50 ng/kg per min) was infused for 180 min alone and during either alpha (phentolamine) or beta (propranolol)-adrenergic blockade in normal subjects under conditions in which plasma insulin, glucagon, and glucose were maintained at comparable levels by infusion of somatostatin (100 mug/h), insulin (0.2 mU/kg per min), and variable amounts of glucose. In additional experiments, to control for the effects of the hyperglycemia caused by epinephrine, variable amounts of glucose without epinephrine were infused along with somatostatin and insulin to produce hyperglycemia comparable with that observed during infusion of epinephrine. This glucose infusion suppressed glucose production from basal rates of 1.8+/-0.1 to 0.0+/-0.1 mg/kg per min (P < 0.01), but did not alter glucose clearance. During infusion of epinephrine, glucose production increased transiently from a basal rate of 1.8+/-0.1 to a maximum of 3.0+/-0.2 mg/kg per min (P < 0.01) at min 30, and returned to near basal rates at min 180 (1.9+/-0.1 mg/kg per min). Glucose clearance decreased from a basal rate of 2.0+/-0.1 to 1.5+/-0.2 ml/kg per min at the end of the epinephrine infusion (P < 0.01). Infusion of phentolamine did not alter these effects of epinephrine on glucose production and clearance. In contrast, infusion of propranolol completely prevented the suppression of glucose clearance by epinephrine, and inhibited the stimulation of glucose production by epinephrine by 80+/-6% (P < 0.001). These results indicate that, under conditions in which plasma glucose, insulin, and glucagon are maintained constant, epinephrine stimulates glucose production and inhibits glucose clearance in man predominantly by beta adrenergic mechanisms.

Overview

CoChat Summary

TL;DR

In normal human subjects with plasma insulin, glucagon, and glucose clamped, epinephrine increased endogenous glucose production transiently and decreased glucose clearance. These effects were predominantly mediated by beta-adrenergic mechanisms, since propranolol largely blocked them while phentolamine did not.

Key findings

  • Epinephrine infusion increased endogenous glucose production from a basal rate of 1.8±0.1 to a maximum of 3.0±0.2 mg/kg per min at min 30, then returned to near basal values (1.9±0.1 mg/kg per min) at min 180; glucose clearance decreased from 2.0±0.1 to 1.5±0.1 ml/kg per min from 90 through 180 min (P < 0.01 vs. basal).
  • Glucose infusion alone, producing comparable hyperglycemia without epinephrine, suppressed endogenous glucose production from 1.8±0.1 to 0.0±0.1 mg/kg per min (P < 0.01) but did not alter glucose clearance.
  • Propranolol completely prevented the suppression of glucose clearance by epinephrine and inhibited epinephrine-stimulated glucose production by 80±6% (P < 0.001).
  • Phentolamine did not significantly alter epinephrine’s effects on glucose production or clearance; the authors conclude that epinephrine stimulates glucose production and suppresses glucose clearance predominantly by beta-adrenergic mechanisms.

Methods

  • Four protocols were performed in five healthy female adult volunteers aged 19–21 yr; all subjects completed protocols A, B, and C, and four completed protocol D.
  • Somatostatin (100 μg/h), insulin (0.2 mU/kg per min), and variable glucose were infused to maintain comparable plasma insulin, glucagon, and glucose levels; epinephrine (50 ng/kg per min) was infused alone or with propranolol or phentolamine.
  • Glucose kinetics were measured with [3-3H]glucose using Steele et al. equations as modified by DeBodo et al.; endogenous glucose production was calculated by subtracting exogenous glucose infusion, and glucose clearance was glucose disappearance divided by plasma glucose. Statistical analysis used two-tailed paired t tests on data from the stable clamp interval 90–180 min.

Limitations

  • The authors state that the studies do not identify the tissues whose glucose clearance was affected by epinephrine or whether the effects were due to direct action on those tissues.
  • The authors state that incomplete reversal of epinephrine-stimulated glucose production by propranolol could indicate a 20% alpha-adrenergic contribution or incomplete beta-adrenergic blockade; they favor incomplete beta blockade, partly because alpha blockade had no measurable effect.
  • The authors note that plasma epinephrine rose about threefold higher during epinephrine plus propranolol than during epinephrine alone, suggesting beta blockade reduces epinephrine clearance; they state this may explain the failure of beta blockade to completely block glucose production.
  • Evident from the text: the sample was very small (five healthy young women, four in one protocol), all subjects were female and within 10% of ideal body weight, and the findings may not generalize to other populations or disease states.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci109714

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 11 Not checked · 35 Own results and interpretations

21 more claims

Create a free account to see all 46 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 7
  • Probably not a substantial claim. 15
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 33 references

Cited by

See all 340

Metadata

Authors
Rizza, R. A., Cryer, P. E., Haymond, M. W., & Gerich, J. E.
Affiliations
Mayo Clinic (US)
Venue
Journal of Clinical Investigation
Published
1980-03-01
Volume
65
Issue
3
Pages
682-689
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2103557599
Cited by
340
References
33
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 6 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 6 · 2014: 9 · 2013: 2 · 2012: 8
FWCI
35.55
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Mayo Foundation for Medical Education and Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
epinephrine, glucose production, glucose clearance, beta-adrenergic receptors, alpha-adrenergic receptors, propranolol, phentolamine, adrenergic blockade, hyperglycemia, glucose infusion, insulin, glucagon, somatostatin
MeSH terms
Adult, Blood Glucose, Epinephrine, Glucagon, Humans, Hyperglycemia, Insulin, Male, Phentolamine, Propranolol, Receptors, Adrenergic, Receptors, Adrenergic, beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man. https://app.cochat.ai/papers/10.1172/jci109714
The paper
Rizza, R. A., Cryer, P. E., Haymond, M. W., & Gerich, J. E. (1980). Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man. Journal of Clinical Investigation. https://doi.org/10.1172/jci109714

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.